Abstract

Aim: Neoadjuvant treatment of locally advanced disease with BRAF inhibitors is expected to increase the likelihood of a R0 resection. We present six patients with stage III unresectable melanoma, neoadjuvantly treated with BRAF inhibitors.

Methods: Patients with unresectable, BRAF-mutated, stage III melanoma, were treated with BRAF inhibitors between 2012 and 2015. Unresectability was determined based on clinical and/or radiological findings. At maximal response, resection was performed. The specimen was reviewed to determine the degree of response.

Results: In five of six patients a radical resection was achieved. Postoperative complications were unremarkable. In five of six resected specimens, vital tumor tissue was found.

Conclusion: Neoadjuvant BRAF inhibitor treatment of locally advanced melanoma is feasible and has the potential to facilitate an R0 resection.

Original languageEnglish
Article numberMMT08
Number of pages10
JournalMelanoma management
Volume5
Issue number2
DOIs
Publication statusPublished - Jun-2018

Keywords

  • PHASE-3
  • CANCER
  • RANDOMIZED CONTROLLED-TRIAL
  • NEOADJUVANT TREATMENT
  • METASTATIC MELANOMA
  • HIGH-RISK
  • SURVIVAL
  • VEMURAFENIB
  • DABRAFENIB
  • IPILIMUMAB

Cite this